Validation and performance comparison of two SARS-CoV-2 IgG/IgM rapid tests

Serological testing for SARS-CoV-2 is a critical component of public health strategies to monitor the spread of the virus. Prior research has shown that molecular techniques like real-time reverse transcriptase PCR remain the gold standard for diagnosing active infections. However, the lack of reliable rapid antibody tests has created a gap in surveillance capabilities. No prior work had resolved the issue of point-of-care antibody testing accuracy. This uncertainty drove the need for evaluating existing rapid tests. Existing studies have proposed that serologic assays could complement PCR testing in tracking immune responses. Yet, the performance of these tests in real-world settings remains unclear. This gap motivated the current investigation into two rapid antibody tests. The study aimed to determine if these tests could be used for diagnostic or surveillance purposes.

The purpose of this investigation was to assess the diagnostic accuracy of two rapid antibody tests for SARS-CoV-2. The study focused on evaluating the IgG/IgM Rapid Test Cassette and the Prima test in clinical settings. The goal was to determine if these tests could serve as reliable tools for point-of-care use or seroprevalence studies. The researchers proposed to validate the tests using blood, serum, and plasma samples from patients. The timing of sample collection was up to 48 days after symptom onset. The study aimed to compare the performance of both tests against established diagnostic standards. The motivation stemmed from the need for accessible and accurate diagnostic tools. The researchers sought to address the limitations of current rapid testing options.

The validation process involved collecting blood, serum, and plasma samples from patients in Saudi Arabia. The samples were obtained from individuals up to 48 days after symptom onset. Both the IgG/IgM Rapid Test Cassette and the Prima test were used for antibody detection. The study compared the results of these tests with reference diagnostic methods. The researchers proposed to assess the sensitivity and specificity of each test. No prior work had resolved the issue of test performance in this context. The study design included a cross-sectional analysis of test outcomes. The comparison aimed to determine the suitability of these tests for clinical use.

The results indicated that both tests showed poor performance in detecting SARS-CoV-2 antibodies. The study found that neither test met the required accuracy standards for clinical use. The IgG/IgM Rapid Test Cassette demonstrated low sensitivity and specificity. The Prima test also failed to provide reliable results in the evaluated timeframe. The researchers reported that these tests cannot be utilised for point-of-care diagnosis. The study found that the tests lack the precision needed for seroprevalence studies. The findings suggest that these tests may not be suitable for widespread implementation. The poor performance of both tests raises concerns about their reliability.

The authors concluded that the two rapid tests evaluated in this study cannot be used for diagnosing SARS-CoV-2 infections. The findings suggest that these tests lack the accuracy required for clinical settings. The researchers proposed that these tests may not be suitable for determining seroprevalence. The study highlights the need for more reliable diagnostic tools for SARS-CoV-2. The poor performance of both tests indicates limitations in their design or application. The authors suggest that further validation is needed before these tests can be utilised. The results indicate that current rapid tests may not meet the standards for clinical use. The study underscores the importance of accurate serologic assays in public health.